Aptose Biosciences (APTO) BidaskScore is lowered to Bought

Aptose Biosciences

The BidaskScore of Aptose Biosciences APTOAPTO shows that the shares of the company are now APTOStrongly Bought Bought by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Strongly Sold since October 22.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Aptose Biosciencesˌ Inc. is a clinical-stage oncology companyˌ which focuses on the discoveryˌ research and development of anticancer therapies. Its product portfolio includes APTO-253ˌ a small molecule that induce expression of the Kruppel-Like Factor 4 (KLF4) genes; and CGʿ806. The company was founded on September 5ˌ 1986 and is headquartered in Torontoˌ Canada.

Aptose Biosciences

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.